Physician profile
Bryan Thomas Burke
NPI 1093031767
$1,251.64
in general payments reported to CMS, 2019-2025
16 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $200 · 2020: $169 · 2021: $179 · 2022: $116 · 2023: $110 · 2024: $311 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $359.84 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $230.91 | 2019-2025 | Eliquis, Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.08 | 2019-2024 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.35 | 2022 | |
| Abbvie INC. | $66.67 | 2023 | Teflaro |
| Gilead Sciences, INC. | $55.77 | 2024 | |
| Pfizer INC. | $50.86 | 2019-2025 | |
| Novo Nordisk INC | $50.77 | 2025 | Ozempic |
| Novartis Pharmaceuticals Corporation | $44.81 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.36 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $33.44 | 2022 | |
| Alexion Pharmaceuticals, INC. | $29.74 | 2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $26.79 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.65 | 2023 | Opsumit |
| Shionogi INC | $22.62 | 2024 | Fetroja |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $20.98 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryan Burke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.